SCHEMBL21494963

SCHEMBL21494963

CCOc1cc(Cl)nc(C)n1

nearest known ligand 0.38

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
LMNA P02545 3/20 0.37
NPC1 O15118 1/20 0.37
MAPK1 P28482 1/20 0.37
RAB9A P51151 1/20 0.37
GRM5 P41594 1/20 0.36
MAPT P10636 2/20 0.35
KMT2A Q03164 1/20 0.35
PDE4D Q08499 3/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PDE4B Q07343 1/20 0.34
S1PR2 O95136 1/20 0.34
GPR35 Q9HC97 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1421836 0.85 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2LMNANPC1MAPK1
SCHEMBL13481260 0.85 MAPT (0.40) ALDH1A1SMN1; SMN2LMNARAB9AMAPT
SCHEMBL10854375 0.82 SMN1; SMN2 (0.38) ALDH1A1SMN1; SMN2LMNANPC1MAPK1
SCHEMBL9432871 0.82 KDM4E (0.39) ALDH1A1SMN1; SMN2LMNANPC1MAPK1
SCHEMBL12204057 0.80 SMN1; SMN2 (0.37) ALDH1A1SMN1; SMN2LMNANPC1MAPK1
SCHEMBL8388439 0.80 POLB (0.41) ALDH1A1SMN1; SMN2LMNANPC1MAPK1
SCHEMBL23949976 0.79 NUDT1 (0.51) ALDH1A1SMN1; SMN2LMNAGRM5MAPT
SCHEMBL30353321 0.79 NUDT1 (0.51) ALDH1A1SMN1; SMN2LMNAGRM5MAPT
SCHEMBL13012202 0.79 SMN1; SMN2 (0.50) ALDH1A1SMN1; SMN2LMNANPC1MAPK1
SCHEMBL1576783 0.78 SMN1; SMN2 (0.55) ALDH1A1SMN1; SMN2LMNANPC1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3870577-B1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK NO 5 LTD (GB) 2025-03-19 EP disclosed
US-20230109662-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2023-04-06 US disclosed
US-11541055-B2 Inhibitors of human immunodeficiency virus replication VIIV Healthcare UK (No.5) Limited (GB) 2023-01-03 US disclosed
CN-113195475-A Inhibitors of human immunodeficiency virus replication VIIV保健英国第五有限公司 2021-07-30 CN disclosed
EP-3781565-A1 2-METHYL-AZA-QUINAZOLINES Bayer Pharma Aktiengesellschaft (DE) 2021-02-24 EP disclosed
US-20200360384-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2020-11-19 US disclosed
WO-2019201848-A1 2-METHYL-AZA-QUINAZOLINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11541055-B2 Inhibitors of human immunodeficiency virus replication EIF2AK2, POLR2E, POLR2H ALDH1A1 2912/4885SMN1; SMN2 2896/4885LMNA 3667/4885
US-20230109662-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR2E, POLR2H ALDH1A1 2912/4885SMN1; SMN2 2896/4885LMNA 3667/4885
US-20200360384-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR2E, POLR2H ALDH1A1 2912/4885SMN1; SMN2 2896/4885LMNA 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.